Equity Analysis /
United States of America

US : Sarepta Therapeutics, Inc. - SRPT | SRP-9001 Study 103 Comparability & Safety Data Encouraging, But Lots Of De-Risking Left To Do

    Danielle Brill
    Daniil Gataulin
    Daniil Gataulin

    Ph.D., Sr. Res. Assoc.

    CGS-CIMB
    18 May 2021
    Published by